Stay updated with breaking news from Catalyst Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
10.05.2022 - Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and ...
The FDA's marketing approval of Jacobus Pharmaceutical’s Ruzurgi (amifampridine) for Lambert-Eaton myasthenic syndrome in pediatric patients is no longer valid.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Greetings and welcome to the Catalyst Pharmaceuticals First Quarter 2021 Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Ms. Alicia Grande, Vice President, Chief Financial Officer and Treasurer. Thank you. You may begin. Alicia Grande -- Vice President, Chief Financial Officer and Treasurer Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's first quarter 2021 financial results and corporate highlights. Leading the call today, we have Patrick McEnany, Chairman and Chief Executive Officer. We are joined by ...